Know Cancer

forgot password

Effects of Pancreaticoduodenectomy on Glucose Metabolism

18 Years
Open (Enrolling)
Diabetes Mellitus, Glucose Intolerance

Thank you

Trial Information

Effects of Pancreaticoduodenectomy on Glucose Metabolism

Questionaire All studied patients will be requested to self-complete a detailed
questionnaire that collects information on demographic data, including usual adult height
and weight, and history of DM in first-degree relatives. Existing medical conditions,
including DM, duration of these medical problems, and current medications will also be
inquired. The database will also include details of weight measured at the time of
recruitment and body mass index (BMI), calculated as weight (kg)/height2 (m2). All studied
patients will have FBG levels measured. Patients receiving prescription antidiabetic
medications for previously diagnosed DM will be classified as having DM regardless of their
FBG value. Among patients not reporting treatment for DM, classification of DM status will
be based on the American Diabetes Association criteria16; patients will be classified as
having DM if the FBG level is ≧126 mg/dL (7 mmol/L), as having impaired fasting glucose
(IFG) if their FBG is between 100 and 125 mg/dL (5.6-6.9 mmol/L), and as having normal
fasting glucose (NFG) if their FBG value is ≦99 mg/dL (5.5 mmol/L).

HOMA insulin resistance assessment (HOMA-IR)

Fasting blood samples will be drawn from all studied patients on the morning of surgery, 6
days later, and again at 1 and 6 months after surgery. Blood for glucose metabolism will be
collected in tubes containing fluoride oxalate, and that for insulin estimation will be
collected in tubes containing EDTA. These latter samples will be kept on ice until plasma
is prepared, following which they will be stored at -70℃ until assayed in batches by
radioimmunoassay. HOMA values will be calculated according to the following formula17:

HOMA=[glucose]mM x [insulin] pM / 22.5 x 6 50 g oral glucose tolerance test All studied
patients will undergo a 2-h oral glucose tolerance test (OGTT) with 50 g glucose before
surgery and at 1 and 6 months after operation. Patients' diabetes medication will be
discontinued 3 days before OGTT. After insertion of an intravenous line, patients will
receive 50 g glucose orally at 8:00 a.m. Blood samples will be collected in chilled EDTA
tubes and centrifuged at 4℃ before storage at -70℃. Plasma concentrations of glucose,
insulin, C-peptide, glucagon, glucose-dependent insulinotropic peptide (GIP), and active
glucagon-like peptide 1 (GLP-1) will be measured at 0, 15, 30, 45, 60, 90, and 120 min
during the 50 g glucose tolerance test.

Measurement of GLP-1 concentration Active GLP-1 concentration will be measured with an
enzyme-linked immunosorbent assay (ELISA) kit (Linco Research Inc.) The intr-assay and
inter-assay coefficient of variations (CVs) will be 7.4% and 8%, respectively. The assay is
100% specific for GLP-1 (7-36) and GLP-1(7-37), and does not react with other forms GLP-1
(1-36 amide, 1-37, 9-36 amide, or 9-37).

Measurement of GIP concentration Total GIP concentrations will be measured with an ELISA kit
(Linco Research Inc.). The assay is 100% specific for GIP 1-42 and GIP 3-42, and does not
cross react with GLP-1, GLP-2, oxyntomodulin, or glucagon. The intra-assay and inter-assay
CVs will be 3.0-8.8% and 1.8-6.1%, respectively.

Measurement of insulin, C-peptide, and glucagon concentrations Insulin and C-peptide will be
measured by chemiluminescence immunoassay (Roche E170, Roche Diagnostics, Indianapolis, IN,
USA). Glucagon concentrations will be measured by radioimmunoassay (Siemens Medical Solution
Diagnostics, Los Angels, CA, USA).

Statistics All data will be analyzed using SPSS Version 11.0 for Windows (SPSS Inc.,
Chicago, IL, USA). Data will be presented as means ± SD unless otherwise stated. Area under
the curve (AUC) values will be calculated using the trapezoidal rule. Comparisons before and
after PD surgery will be made using the Wilcoxon signed rank-sum test. P -values<0.05 will
be considered significant.

Inclusion Criteria:

- Patients receiving pancreaticoduodenectomy

Exclusion Criteria:

- history of pancreatitis

- hepatic dysfunction (Child-Pugh > 2)

- renal dysfunction (serum creatinine concentration > 3 mg/L, hemodialysis, or both)

- pregnancy

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Change of glucose metabolism after pancreaticoduodenectomy

Outcome Description:

response of 50 g oral glucose tolerance test, Measurement of glucagon-like peptide-1, Measurement of insulin, C-peptide, and glucagon concentrations

Outcome Time Frame:

on the morning of surgery (day 1), 6 days later, and again at 1 and 6 months after surgery.

Safety Issue:


Principal Investigator

Yu-Wen Tien, M.D., Ph.D.

Investigator Role:

Study Chair

Investigator Affiliation:

National Taiwan University Hospital


Taiwan: Department of Health

Study ID:




Start Date:

November 2011

Completion Date:

May 2013

Related Keywords:

  • Diabetes Mellitus
  • Glucose Intolerance
  • Pancreaticoduodenectomy
  • diabetes
  • sugar metabolism
  • Diabetes Mellitus
  • Glucose Intolerance